Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Kleinman

Showing results (151-160 of 185) with videos related to

Pageof 19
Sort By:
Nature Communications|July 22, 2025
Aberrant EZHIP expression drives tumorigenesis in osteosarcomaWajih Jawhar, Geoffroy Danieau, Alva Annett, et al.
Blood Advances|March 15, 2021
Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesiclesNadim Tawil, Rayhaan Bassawon, Brian Meehan, et al.
Nature Communications|June 30, 2019
Mutant H3 histones drive human pre-leukemic hematopoietic stem cell expansion and promote leukemic aggressivenessMeaghan Boileau, Margret Shirinian, Tenzin Gayden, et al.
Cell Reports|March 22, 2024
Evolution of chromosome-arm aberrations in breast cancer through genetic network rewiringElena Kuzmin, Toby M Baker, Tom Lesluyes, et al.
Nature Immunology|September 15, 2025
A spatial map of MAPK-activated immunosuppressive myeloid populations in pediatric low-grade gliomaAugusto Faria Andrade, Romain Sigaud, Evan Puligandla, et al.
Cancer Cell|May 16, 2019
Pervasive H3K27 Acetylation Leads to ERV Expression and a Therapeutic Vulnerability in H3K27M GliomasBrian Krug, Nicolas De Jay, Ashot S Harutyunyan, et al.
Nature Communications|June 4, 2021
STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancerStephanie P Totten, Young Kyuen Im, Eduardo Cepeda Cañedo, et al.
Cancer Cell|September 19, 2019
Pervasive H3K27 Acetylation Leads to ERV Expression and a Therapeutic Vulnerability in H3K27M GliomasBrian Krug, Nicolas De Jay, Ashot S Harutyunyan, et al.
NPJ Precision Oncology|August 14, 2025
A review of diffuse hemispheric glioma, H3 G34-mutant disease development, DNA repair, microenvironment, and treatments on the horizonCameron Crowell, Ziwen Zhu, Yingxiang Li, et al.
Science Translational Medicine|October 13, 2021
Epigenetically defined therapeutic targeting in H3.3G34R/V high-grade gliomasStefan R Sweha, Chan Chung, Siva Kumar Natarajan, et al.
Pageof 19

Showing results (151-160 of 185) with videos related to

Sort By:
Pageof 19
Nature Communications|July 22, 2025
Aberrant EZHIP expression drives tumorigenesis in osteosarcomaWajih Jawhar, Geoffroy Danieau, Alva Annett, et al.
Blood Advances|March 15, 2021
Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesiclesNadim Tawil, Rayhaan Bassawon, Brian Meehan, et al.
Nature Communications|June 30, 2019
Mutant H3 histones drive human pre-leukemic hematopoietic stem cell expansion and promote leukemic aggressivenessMeaghan Boileau, Margret Shirinian, Tenzin Gayden, et al.
Cell Reports|March 22, 2024
Evolution of chromosome-arm aberrations in breast cancer through genetic network rewiringElena Kuzmin, Toby M Baker, Tom Lesluyes, et al.
Nature Immunology|September 15, 2025
A spatial map of MAPK-activated immunosuppressive myeloid populations in pediatric low-grade gliomaAugusto Faria Andrade, Romain Sigaud, Evan Puligandla, et al.
Cancer Cell|May 16, 2019
Pervasive H3K27 Acetylation Leads to ERV Expression and a Therapeutic Vulnerability in H3K27M GliomasBrian Krug, Nicolas De Jay, Ashot S Harutyunyan, et al.
Nature Communications|June 4, 2021
STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancerStephanie P Totten, Young Kyuen Im, Eduardo Cepeda Cañedo, et al.
Cancer Cell|September 19, 2019
Pervasive H3K27 Acetylation Leads to ERV Expression and a Therapeutic Vulnerability in H3K27M GliomasBrian Krug, Nicolas De Jay, Ashot S Harutyunyan, et al.
NPJ Precision Oncology|August 14, 2025
A review of diffuse hemispheric glioma, H3 G34-mutant disease development, DNA repair, microenvironment, and treatments on the horizonCameron Crowell, Ziwen Zhu, Yingxiang Li, et al.
Science Translational Medicine|October 13, 2021
Epigenetically defined therapeutic targeting in H3.3G34R/V high-grade gliomasStefan R Sweha, Chan Chung, Siva Kumar Natarajan, et al.
Pageof 19